Valneva shares fall after it withdraws chikungunya vaccine applications in US

Valneva SE

20/01/2026 08:31

** Shares in French vaccine maker Valneva VLS.PA fall 6.4%, paring losses after falling around 14%, after withdrawing biologics license (BLA) and investigational new drug (IND) applications in the U.S for chikungunya vaccine Ixchiq

** Brokerage Van Lanschot Kempen says decision appears to be driven by continued license suspension and FDA's placing IND on clinical hold while investigating a newly reported adverse event in a younger adult

** "We believe it is the right decision to stop investing resources," Kempen says, highlighting limited sales impact and minor valuation contribution from Ixchiq

** Stifel echoes these comments, seeing the decision as rational given the limited visibility on potential resumption of commercialisation

(Reporting by Leo Marchandon in Gdansk)

((leo.marchandon@thomsonreuters.com;))